利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.063 秒)

    COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS
    6.
    发明申请
    COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS 审中-公开
    包含5-LIPOXYGENASE激活蛋白抑制剂和硝酸氧化物调节剂的组合物和治疗

    公开(公告)号：US20100068301A1

    公开(公告)日：2010-03-18

    申请号：US12517166

    申请日：2007-11-30

    申请人： John H. Hutchinson ,  Mustapha Haddach ,  Mark Moran ,  Jillian Evans ,  Nicholas Simon Stock ,  Jeffrey Roger Roppe

    发明人： John H. Hutchinson ,  Mustapha Haddach ,  Mark Moran ,  Jillian Evans ,  Nicholas Simon Stock ,  Jeffrey Roger Roppe

    IPC分类号： A61K31/4709 ,  A61K31/404 ,  C07D401/12 ,  A61K33/26 ,  A61K31/04 ,  A61K31/34 ,  A61K31/195 ,  A61K31/7076 ,  A61K38/08 ,  A61P9/12

    CPC分类号： A61K45/06 ,  A61K31/195 ,  A61K31/404 ,  A61K31/47 ,  A61K2300/00

    摘要： Disclosed herein are compositions and compounds that combine an inhibitor of 5-lipoxygenase activating protein (FLAP) and a modulator of NO levels in a mammal. The NO modulator can be an agent that induces the production of NO in a mammal, or can be an agent that itself produces NO in the mammal. Further disclosed herein are strategies for synthesizing such compounds, and methods for testing whether the combination compounds and compositions provide a desired benefit. Also disclosed herein are pharmaceutical compositions and formulations that combine a FLAP inhibitor and an NO modulator. Further described herein are methods for using such compositions and compounds for the treatment of diseases, conditions, and disorders in a mammal, including a human. Such treatment methods include the separate administration of a FLAP inhibitor and a NO modulator to the mammal, and the simultaneous administration of a FLAP inhibitor and a NO modulator to the mammal.

    摘要翻译： 本文公开了在哺乳动物中组合5-脂氧合酶活化蛋白（FLAP）抑制剂和NO水平调节剂的组合物和化合物。 NO调节剂可以是诱导哺乳动物产生NO的药剂，或者可以是本身在哺乳动物中产生NO的药剂。 本文进一步公开的是合成这些化合物的策略，以及用于测试组合化合物和组合物是否提供期望益处的方法。 本文还公开了组合FLAP抑制剂和NO调节剂的药物组合物和制剂。 本文进一步描述的是使用这些组合物和化合物治疗哺乳动物，包括人类的疾病，病症和障碍的方法。 这样的治疗方法包括向哺乳动物分开施用FLAP抑制剂和NO调节剂，以及向哺乳动物同时施用FLAP抑制剂和NO调节剂。